| Sign In to gain access to subscriptions and/or personal tools. |
Eszopiclone ingestions reported to Texas poison control centers, 2005—2006Texas Department of State Health Services, 1100 W 49th Street, Austin, TX 78756, USA, mathias.forrester{at}dshs.state.tx.us
Eszopiclone is a nonbenzodiazepine hypnotic for the treatment of insomnia and classified as schedule IV controlled substance. Limited information exists on eszopiclone ingestions reported to poison control centers. The distribution of eszopiclone ingestions reported to Texas poison control centers during 2005—2006 was determined for various factors. In addition, triage guidelines for the management of such ingestions were drafted. Of 525 total eszopiclone ingestions, 259 involved coingestants. Of coingestant cases, 78.8% involved suspected attempted suicide and 90.7% were managed at a healthcare facility. Of 266 ingestions of eszopiclone alone, 40.2% were suspected attempted suicide and 62.0% were managed at a healthcare facility. A final medical outcome and dose ingested were known for 60 ingestions of eszopiclone alone. The mean dose was 28.3 mg (range 0.3—210 mg). Ingestions of eszopiclone alone of
Key Words: adverse exposures • eszopiclone • management • poison control centers
Human & Experimental Toxicology, Vol. 26, No. 10,
795-800 (2007) |
|||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
6 and >6 mg differed with respect to the proportion involving suspected attempted suicide (0.0% versus 64.7%), final medical outcome of minor or moderate effect (38.5% versus 67.6%) and management at a healthcare facility (34.6% versus 91.2%). Using 6 mg as a threshold dose for referral to a healthcare facility, 78% of cases not already at/en route to a healthcare facility were managed according drafted triage guidelines. Human & Experimental Toxicology (2007) 26, 795—800